From editor-in-chief

Here is the first issue of the journal Good Clinical Practice for the year 2026. However, this issue is not just another publication. Today, we celebrate an important anniversary: exactly 25 years ago, in 2001, the first issue of our journal was released.

A quarter of a century is a significant milestone. Over this time, Good Clinical Practice has evolved from a modest specialised publication into one of the leading scientific and practical journals in the fields of clinical research, pharmacoeconomics, standardisation, and health technology assessment. Looking back today, I can proudly say that throughout this period we have remained true to our principles — to publish only high-quality, peer-reviewed materials that help physicians, researchers, and healthcare administrators make well-founded decisions.

This anniversary issue continues the tradition of publishing scientific and clinical materials that reflect current approaches in diagnostics, therapy, and pharmacotherapy. It is devoted to pertinent issues in medicine, combining innovative treatment methods with the optimisation of patient management in cases of multiple comorbid conditions.

The focus of this issue is clinical pharmacology, in particular, the use of monoclonal antibodies in the prevention and treatment of COVID-19. A literature review prepared by a team of authors from the Pirogov Russian National Research Medical University (RNRMU) analyses the therapeutic value of monoclonal antibody‑based drugs, their efficacy in reducing viral load, hospitalisation rates, and mortality in at‑risk patients. Special attention is paid to safety issues, effectiveness against new viral strains, and the integration of these drugs into clinical practice.

This issue also presents clinical cases illustrating the successful long‑term use of guselkumab in a patient with severe psoriasis and multiple comorbidities. This example confirms the possibility of achieving sustained disease control even in complex clinical situations. Another case is devoted to the analysis of drug interaction between valproic acid and meropenem in children, highlighting the importance of therapeutic drug monitoring for ensuring the safety of pharmacotherapy in paediatric practice.

In the section dedicated to internal medicine, the results of a study applying the STOPP/START criteria in elderly patients with atrial fibrillation and stage 4 chronic kidney disease are presented. The data obtained indicate the need for further optimisation of pharmacotherapy in polymorbid patients and the importance of using such tools in real‑world clinical practice.

Special attention is paid to issues of pharmacoepidemiology and drug supply, including the organisation of patient registries, digitalisation of clinical research, as well as pharmacoeconomic aspects of developing the drug supply system in Russia. In this context, a historical article on the formation of pharmacoeconomics and clinical‑economic analysis in our country is particularly valuable — a living testament to how the national professional school was established.

Furthermore, the issue addresses biomedical ethics in the era of convergent technologies, which is especially relevant given the rapid development of biomedical innovations.

An anniversary is not only a date but also an occasion to express gratitude. I thank the members of the editorial board, reviewers, authors, and, of course, our readers. Without your support, trust, and active participation, the journal would not have succeeded. This issue clearly demonstrates how modern scientific data can be integrated into everyday clinical practice to improve the quality of medical care.

We hope that the materials in this issue will prove useful to physicians, researchers, and healthcare administrators. We wish you productive reading, new professional discoveries, and that you stay with us for the next 25 years.

Respectfully yours,

Sergey Zyryanov
Editor‑in‑Chief of the journal Good Clinical Practice